Oesophageal disorders: Future developments

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 6, 2002, Pages 811-833

  Tam, William ^a   Dent, John ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Adenocarcinoma; Barrett's oesophagus; Chemoprevention; Drug therapy; Endoscopy; Luminal anti reflux therapy; Reflux disease; Surveillance; Symptoms

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; BY 841; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CISAPRIDE; CYCLOOXYGENASE 2; DIGESTIVE TRACT AGENT; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTEIN P16; PROTEIN P53; PROTON PUMP INHIBITOR; REFLUX INHIBITOR; REVERSIBLE ACID PUMP INHIBITOR; SUCRALFATE; UNCLASSIFIED DRUG; VILLIN; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; NITROSAMINE;

ADENOCARCINOMA; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS MUCOSA; FUTUROLOGY; GASTROESOPHAGEAL REFLUX; HUMAN; MORTALITY; OPTICAL RESOLUTION; REVIEW; RISK ASSESSMENT; STOMACH CANCER; SYMPTOMATOLOGY; ANIMAL; ESOPHAGUS TUMOR; FORECASTING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CHROMOENDOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG INHIBITION; DRUG SAFETY; ENDOPROSTHESIS; ENDOSCOPIC SURGERY; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SURGERY; HEALTH CARE COST; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; LAPAROSCOPIC SURGERY; MOTOR DYSFUNCTION; PREVALENCE; RADIOFREQUENCY ABLATION; REFLUX ESOPHAGITIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; STOMACH FUNDOPLICATION; SUTURING METHOD;

ADENOCARCINOMA; ANIMALS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FORECASTING; GASTROESOPHAGEAL REFLUX; HUMANS;

EID: 0036886213     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0350     Document Type: Article

References (93)

1. Dent, J, Brun, J, & Fendrick, A M et al. (1999). An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut, 44 (supplement 2) S1-S16.
2. Lundell, L R, Dent, J, & Bennett, J R et al. (1999). Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut, 45 172-180.
3. Blustein, P K, Back, P L, & Meddings, J B et al. (1998). The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. American Journal of Gastroenterology, 93 2508-2512.
4. Shaw, M J, Talley, N J, & Beebe, T J et al. (2001). Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. American Journal of Gastroenterology, 96 52-57.
5. Kahrilas, P J, Falk, G W, & Johnson, D A et al. (2000). Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Alimentary Pharmacology and Therapeutics, 14 1249-1258.
6. Richter, J E, Kahrilas, P J, & Johanson, J et al. (2001). Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. American Journal of Gastroenterology, 96 656-665.
7. Castell, D O, Kahrilas, P J, & Richter, J E et al. (2002). Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. American Journal of Gastroenterology, 97 575-583.
8. Bytzer, P, Havelund, T, & Møller, Hansen (1993). Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scandinavian Journal of Gastroenterology, 28 119-125.
9. Vieth, M, Delarive, J, Dent, J, et al. Red streaks in the oesophagus in patients with reflux oesophagitis: what are the histomorphological correlates?, Scandinavian Journal of Gastroenterology, 2001, 36(11), 1123-1127
10. Tam, W, Dent, J, Conroy-Hiller, T, & Schoeman, M N (2001). Proposed new endoscopic criteria for minimal change reflux esophagitis based on magnification endoscopy. Gastrointestinal Endoscopy, 53 AB119.
11. Tam, W, Edebo, A, & Bruno, M et al. (2002). Endoscopy-negative reflux disease (ENRD): high-resolution endoscopic and histological signs. Gastroenterology, 122 A-74.
12. Holloway, R H, Dent, J, Narielvala, F, & Mackinnon, A M (1996). Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut, 38 649-654.
13. Andersson, T, Rohss, K, & Bredberg, E et al. (2001). Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Alimentary Pharmacology and Therapeutics, 15 1563-1569.
14. Edwards, S J, Lind, T, & Lundell, L (2001). Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Alimentary Pharmacology and Therapeutics, 15 1729-1736.
15. Adachi, K, Fujishiro, H, & Katsube, et al. (2001). Reflux esophagitis: effect of position, nocturnal acid reflux. Journal of Gastroenterology and Hepatology, 16 1191-1196.
16. Howden, C W, Henning, J M, & Huang, B et al. (2001). Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies [erratum appears in Am J Gastroenterol 2001; 96: 2809]. American Journal of Gastroenterology, 96 1704-1710.
17. Inadomi, J M, Jamal, R, & Murata, G H et al. (2001). Step-down management of gastroesophageal reflux disease. Gastroenterology, 121 1095-1100.
18. Ofman, J J, Dorn, G H, & Fennerty, M B et al. (2002). The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 16 261-273.
19. Kahrilas, P J (2001). Surgical therapy for reflux disease. Journal of the American Medical Association, 285 2376-2378.
20. Crawley, J A, & Schmitt, C M (2000). How satisfied are chronic heartburn sufferers with their prescription medications? Results of the unmet needs survey. J Clin Outcomes Management, 7(11) 29-34.
21. Klinkenberg-Knol, E C, Nelis, F, & Dent, J et al. (2000). Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology, 118 661-669.
22. Lamberts, R, Brunner, G, & Solcia, E (2001). Effects of very long (up to 10 year) proton pump blockade on human gastric mucosa. Digestion, 64 205-213.
23. Vermeer, I TM, Engels, G JB, & Pachen, D MF A et al. (2001). Intragastric volatile N-nitrosamines, nitrite, pH, and Helicobacter pylori during long-term treatment with omeprazole. Gastroenterology, 121 517-525.
24. Iijima, K, Henry, E, & Moriya, A et al. (2002). Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology, 122 1248-1257.
25. McColl, K EL, Dickson, A, & El-Nujumi, A et al. (2000). Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. American Journal of Gastroenterology, 95 101-105.
26. Moayyedi, P, Feltbower, R, & Brown, J et al. (2000). The effect of population H. pylori screening and treatment on dyspepsia and quality of life in the community: results of a randomised controlled trial. Lancet, 355 1665-1669.
27. Moayyedi, P, Bardhan, C, & Young, L et al. (2001). Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology, 121 1120-1126.
28. Dent, J (2001). Is Helicobacter pylori relevant in the management of reflux disease [review]?. Alimentary Pharmacology and Therapeutics, 15 16-21.
29. Hamada, H, Haruma, K, & Mihara, M et al. (2000). High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Alimentary Pharmacology and Therapeutics, 14 729-735.
30. Wu, J CY, Sung, J JY, & Chan, F KL et al. (2000). Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 14 427-432.
31. Stolte, M, Meining, A, & Schmitz, J M et al. (1998). Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 12 247-253.
32. Kuipers, E J, Nelis, G F, & Klinkenberg-Knol, E C et al. (2001). Helicobacter pylori eradication for the prevention of atrophic gastritis during omeprazole therapy: a prospective randomized trial. Gastroenterology, 120 (supplement I): A-14.
33. Malfertheiner, P, Megraud, F, & O'Morain, C et al. (2002). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Alimentary Pharmacology and Therapeutics, 16 167-180.
34. Wurst, W, & Hartmann, M (1996). Current status of acid pump antagonists (reversible PPIs). Yale Journal of Biology and Medicine, 69 233-243.
35. Van Herwaarden, M A, Samsom, M, & Smout, A JP M (2000). Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology, 119 1439-1446.
36. Hirsch, D P, Tytgat, G NJ, & Boeckxstaens, G EE (2002). Review article: transient lower oesophageal sphincter relaxations - a pharmacological target for gastro-oesophageal reflux disease?. Alimentary Pharmacology and Therapeutics, 16 17-26.
37. Tack, J, & Sifrim, D (2002). Anti-relaxation therapy in GORD. Gut, 50 6-7.
38. B agonist baclofen in normal subjects. Gastroenterology, 118 7-13.
39. B agonist baclofen in patients with gastro-oesophageal reflux disease. Gut, 50 19-24.
40. Trudgill, N J, Hussain, F N, & Moustafa, M et al. (2001). The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Alimentary Pharmacology and Therapeutics, 15 1357-1364.
41. Lafullarde, T, Watson, D I, & Jamieson, G G et al. (2001). Laparoscopic Nissen fundoplication. Five-year results and beyond. Archives of Surgery, 136 180-184.
42. Bammer, J, Hinder, R A, Klaus, A, & Klingler, P J (2001). Five- to eight-year outcome of the first laparoscopic Nissen fundoplications. Journal of Gastrointestinal Surgery, 5 42-48.
43. Lundell, L, Miettinen, P, & Myrvold, H E et al. (2001). Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gatsroesophageal reflux disease. Journal of the American College of Surgeons, 192 172-181.
44. Bais, J E, Bartelsman, J F, & Bonjer, H J et al. (2000). Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. Lancet, 355 170-174.
45. Vakil, N, Treml, S, Shaw, M, Kirby, R, The outcome of laparoscopic fundoplication for reflux diseases in community practice in the USA, American Journal of Medicine (in press).
46. Filipi, C J, Lehman, G A, & Rothstein, R I et al. (2001). Transoral, flexible endoscopic suturing for treatment of GERD: a multi-center trial. Gastrointestinal Endoscopy, 53 416-422.
47. Tam, W, Holloway, R H, Dent, J, & Schoeman, M N (2002). Impact of endoscopic suturing of the gastroesophageal junction on lower esophageal sphincter function and gastroesophageal reflux in patients with reflux disease. Gastroenterology, 122 A-47.
48. Triadafilopoulos, G, Dibaise, J K, & Nostrant, T T et al. (2002). The Stretta procedure for the treatment of GERD: 6and 12 month follow-up of the U.S. open label trial. Gastrointestinal Endoscopy, 55 149-156.
49. Corley, D A, Katz, P O, & Wo, J M et al. (2002). Radiofrequency energy to the gastroesophageal junction for treatment of GERD (the Stretta procedure): a randomized, sham-controlled, multi-center clinical trial [abstract]. Gastrointestinal Endoscopy, 55 AB100.
50. Kim, M S, Dent, J, & Holloway, R H et al. (2000). Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation in a canine model [abstract]. Gastrointestinal Endoscopy, 118 AB860.
51. DiBaise, J K, Brand, R E, & Quigley, E M (2002). Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. American Journal of Gastroenterology, 97 833-842.
52. Tam, W, Schoeman, M N, & Zhang, Q et al. (2001). Delivery of radiofrequency energy (RFe) to the lower esophageal sphincter (LES) and gastric cardia inhibits transient LES relaxations and gastroesophageal reflux in patients with reflux disease [abstract]. Gastroenterology, 120 A-16.
53. Feretis, C, Benakis, P, & Dimopoulos, C et al. (2001). Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointestinal Endoscopy, 43 423-426.
54. Mason, R J, Hughes, M, & Lehman, G A et al. (2002). Endoscopic augmentation of the cardia with a biocompatible injectable polymer (Enteryx) in a porcine model. Surgical Endoscopy, 16 386-391.
55. Lehman, G A, Aisenberg, J, & Cohen, L B et al. (2002). Enteryx solution, a minimally invasive injectable treatment for GERD: international multicenter trial results. Gastrointestinal Endoscopy, 55 AB101.
56. Fockens, P, Costamagna, G, & Gabbrielli, A et al. (2002). Endoscopic augmentation of the lower esophageal sphincter (LES) for the treatment of GERD: multicenter study of the Gatekeeper reflux repair system. Gastrointestinal Endoscopy, 55 AB90.
57. Sampliner, R E, Garewal, H S, & Fennerty, M B et al. (1990). Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Digestive Diseases and Sciences, 35 93-96.
58. Endo, T, Awakawa, T, & Takahashi, H et al. (2002). Classification of Barrett's epithelium by magnifying endoscopy. Gastrointestinal Endoscopy, 55 641-647.
59. Sharma, P, Topalovski, M, & Mayo, M S et al. (2001). Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointestinal Endoscopy, 54 289-293.
60. Latchford, A, Eksteen, B, & Jankowski, J (2001). The continuing tale of cytokeratins in Barrett's mucosa: as you like it. Gut, 49 746-749.
61. El-Rifai, W, Frierson, H F, & Moskaluk, C A et al. (2001). Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology, 121 592-598.
62. Sharma, P (2001). Short segment Barrett esophagus and specialized columnar mucosa at the gastroesophageal junction. Mayo Clinical Proceedings, 76 331-334.
63. Hirota, W K, Loughney, T M, & Lazas, D J et al. (1999). Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology, 116 277-285.
64. Benipal, P, Garewal, H S, & Sampliner, R E et al. (2001). Short-segment Barrett's esophagus: relationship of age with extent of intestinal metaplasia. American Journal of Gastroenterology, 96 3084-3088.
65. Weston, A P, Krmpotich, P T, & Cherian, R et al. (1997). Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. American Journal of Gastroenterology, 92 407-413.
66. Rudolph, R E, Vaughan, T L, & Storer, B E et al. (2000). Effect of segment length on risk for progression in patients with Barrett's esophagus. Annals of Internal Medicine, 132 612-620.
67. Weston, A P, Sharma, P, & Topalovski, M et al. (2000). Long-term follow-up of Barrett's high-grade dysplasia. American Journal of Gastroenterology, 95 1888-1893.
68. Wijnhoven, B PL, Louwman, M WJ, Tilanus, H W, & Coebergh, J-W W (2002). Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s. European Journal of Gastroenterology and Hepatology, 14 115-122.
69. Forman, D (2002). Counting cancers at the junction - a problem of routine statistics. European Journal of Gastroenterology and Hepatology, 14 99-101.
70. Jankowski, J A, Provenzale, D, & Moayyedi, P (2002). Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology, 122 588-595.
71. Spechler, S J (2000). Barrett's esophagus: an overrated cancer risk factor. Gastroenterology, 119 587-589.
72. El-Serag, H B, Mason, A C, & Petersen, N et al. (2002). Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut, 50 368-372.
73. Dacosta, R S, Wilson, B C, & Marcon, N E (2002). New optical technologies for earlier endoscopic diagnosis of premalignant gastrointestinal lesions. Journal of Gastroenterology and Hepatology, 17 (supplement) S86-S105.
74. Krishnadath, S, Wang, K, & Halling, K et al. (2002). Detection of cytogenetic abnormalities by multi-color FISH in brush cytology specimens of Barrett's esophagus. Gastroenterology, 122 A289.
75. Krishnadath, K K, Reid, B J, & Wang, K K (2001). Biomarkers in Barrett esophagus. Mayo Clinic Proceedings, 76 438-446.
76. Corley, D A, Levin, T R, & Habel, L A et al. (2002). Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology, 122 633-640.
77. Dulai, G S, Guha, S, & Kahn, K L et al. (2002). Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology, 122 26-33.
78. Lagergren, J, Bergstrom, R, Lindgren, A, & Nyren, O (1999). Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New England Journal of Medicine, 340 825-831.
79. Shirvani, V N, Ouatu-Lascar, R, & Kaur, B S et al. (2000). Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology, 118 487-496.
80. Ye, W, Chow, W- H, & Lagergren, J et al. (2001). Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology, 121 1286-1293.
81. Thun, M J, Namboori, M M, & Calle, E E et al. (1993). Aspirin use and risk of fatal cancer. Cancer Research, 53 1322-1327.
82. Funkhouser, E M, & Sharp, G B (1995). Aspirin and reduced risk of esophageal carcinoma. Cancer, 76 1116-1119.
83. Farrow, D C, Vaughan, T L, & Hansten, P D et al. (1998). Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer, Epidemiology, Biomarkers and Prevention, 7 97-102.
84. Li, M, Lotan, R, & Levin, B et al. (2000). Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer, Epidemiology, Biomarkers and Prevention, 9 545-549.
85. Souza, R F, Shewmake, K, & Beer, D G et al. (2000). Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Research, 60 5767-5772.
86. Morris, C D, Armstrong, G R, & Bigley, G et al. (2001). Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. American Journal of Gastroenterology, 96 990-996.
87. Buttar, N S, Wang, K K, & Leontovich, O et al. (2002). Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 122 1101-1112.
88. Sampliner RE and the Practice Parameters of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and the therapy of Barret's esophagus. American Journal of Gastroenterology 1998; 93: 1028-1032.
89. Provenzale, D, Schmitt, C, & Wong, J B (1999). Barrett's esophagus: a new look at surveillance based on emerging rates of cancer risk. American Journal of Gastroenterology, 94 2043-2053.
90. Sampliner, R E, Faigel, D, & Fennerty, M B et al. (2001). Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointestinal Endoscopy, 53 554-558.
91. Fennerty, M B, Corless, C L, & Sheppard, B et al. (2001). Pathological documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy. Gut, 49 142-144.
92. Van Laethem, J L, Peny, M O, & Salmon, I et al. (2000). Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut, 46 574-577.
93. Shand, A, Dallal, H, & Palmer, K et al. (2001). Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut, 48 580-581.